

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0030
Drug name and formulations:		Toujeo®- insulin glargine 300 units/mL
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Unacceptably high risk of wrong dose medication errors.
Clinical effectiveness	<i>Established licensed product</i>	No convincing clinical advantages over established formulary option.
Strength of evidence		Evidence presented around reduced hypoglycaemia was weak. No evidence presented for patient benefit of lower volume of injection.
Cost effectiveness or resource impact	£	More expensive than Abasaglar®, cost neutral compared to Lantus®.
Place of therapy relative to available treatments	<i>1/2nd tier</i>	Cannot see any.
National guidance and priorities	<i>NICE, MTRAC</i>	SMC approved
Local health priorities	<i>CCG views</i>	CCGs not supporting due to concerns around introducing significant risk into the system.
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	None identified
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	N/A

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	Not approved. The risk benefit ratio is unfavourable, and this is not a cost effective option.
Formulary status (RAG) and rationale	
Implementation requirements:	
Implementation monitoring:	